Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia

Bekele Afessa, Andrew F. Shorr, Antonio R. Anzueto, Donald E. Craven, Regina Schinner, Marin H. Kollef

Research output: Contribution to journalArticle

39 Scopus citations


Background: A silver-coated endotracheal tube (ETT) reduced the incidence of ventilator-associated pneumonia (VAP) compared with an uncoated ETT in the North American Silver-Coated Endotracheal Tube (NASCENT) study. Methods: To evaluate the effect of an ETT and risk factors on mortality, we performed a retrospective cohort analysis in patients who developed VAP in the NASCENT study. We determined causes of death and VAP due to potentially multidrug-resistant bacteria (eg, Pseudomonas, Acinetobacter ) and performed stepwise multivariate logistic regression with the following predefined variables: treatment group, Acute Physiology and Chronic Health Evaluation (APACHE) II score, continuous sedation, coma, COPD, emergency surgery/trauma, immunodefi ciency, potentially multidrug-resistant bacteria, and inappropriate initial antibiotics. Results: The silver-coated ETT was associated with reduced mortality in patients with VAP (silver vs control, 5/37 [14%] vs 20/56 [36%], P =.03), but not in those without VAP (228/729 [31%] vs 178/687 [26%], P =.03). The only between-group difference in leading causes of death was respiratory failure (silver vs control, 45/233 [19%] vs 22/198 [11%], P =.02). Of the VAP-related deaths, one in the silver group was caused by Acinetobacter sepsis. In the control group, six deaths were caused by sepsis and three by pneumonia; six of nine pathogens were potentially multidrug resistant. In multivariate analysis, the treatment group was a predictor of mortality (odds ratio, silver vs control, 0.28; 95% CI, 0.09-0.89;P =.03). APACHE II ≥ 20 and inappropriate antibiotics also remained in the model ( P<.1). Conclusions: These fi ndings suggest that a silver-coated ETT was associated with reduced mortality in patients who developed VAP in the NASCENT study. Studies are needed to confirm these exploratory findings.

Original languageEnglish (US)
Pages (from-to)1015-1021
Number of pages7
Issue number5
StatePublished - May 1 2010


ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this